Veltassa
(Patiromer)Phase 3Small molecule
Patiromer is used to treat high potassium levels in the blood by helping the body remove excess potassium through the digestive system.[1] Veltassa is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]
Veltassa is one of 51 small molecule programs targeting Chronic Kidney Disease. It is currently in Phase 3.
3
Indications
22
Total Trials
3
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
172 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Veltassa
VVifor Pharma
Phase 3
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Januvia
ZZydus Therapeutics Inc.
Preclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hyperkalemia7 trials
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
Completed·—·Phase 4·NCT03781089·36 enrolled
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Completed·—·Phase 4·NCT02933450·43 enrolled
Show 4 more trials
Chronic Kidney Disease5 trials
Heart Failure3 trials
Kidney Disease1 trial
5 more indications
Renal Transplant Recipients1 trial
Diabetic Nephropathy1 trial
Hemodialysis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Patiromer. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VVifor Pharma